Oculis Holding (OCS) AI Stock Analysis

• Market Cap: $955.98M
• Dividend Yield: N/A
• Average Volume (3M): 11.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.42
• Revenue Growth: N/A
• EPS Growth: -43.02%
• Country: US
• Employees: 49
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.60
• Shares Outstanding: 54,533,672
• 10 Day Avg. Volume: 9,648
• 30 Day Avg. Volume: 11,235
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 2.91K
• Enterprise Value/Gross Profit: -44.02
• Enterprise Value/Ebitda: -6.94
• 1Y Price Target: $33.17
• Price Target Upside: 91.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 41 Neutral
• Price Target: $17.00 ▼(-1.85% Downside)

Oculis Holding's overall stock score is primarily impacted by its poor financial performance, with significant operational losses and declining equity. Technical analysis indicates a bearish trend, and the valuation is challenging due to negative earnings. The absence of earnings call insights and corporate events leaves the financial and technical factors as the primary drivers of the score.

Positive Factors

Clinical Trials

Enrollment for the pivotal phase 3 trials of OCS-01 in DME is complete, keeping the program on track for a key topline data readout.

Financial Stability

With cash runway extended into early 2028, Oculis is well-funded through key data catalysts.

Product Development

OCS-01 aims to be the first non-invasive therapy for DME, potentially expanding the market to patients who typically go untreated.

Negative Factors

Market Competition

There are high unmet needs in treatment for conditions Privosegtor targets, with no approved therapies available.

Regulatory Challenges

Management has made a strategic decision to submit the New Drug Application for OCS-01 for the treatment of inflammation and pain following ocular surgery after the NDA submission for diabetic macular edema.

Oculis Holding Business Overview & Revenue Model

Company Description

Oculis Holding (OCS) is a biopharmaceutical company focused on the development of innovative treatments for eye diseases. The company operates primarily in the ophthalmology sector, specializing in drug delivery systems and therapies aimed at addressing a range of ocular conditions. Oculis is committed to advancing its proprietary technologies to improve patient outcomes and enhance the quality of life for individuals suffering from vision impairments.

How the Company Makes Money

Oculis generates revenue through the development and commercialization of its ophthalmic products. The primary revenue streams include sales of its proprietary drug formulations, licensing agreements with pharmaceutical companies, and collaborations with research institutions and healthcare providers. Oculis may also engage in partnerships that involve joint development of new therapies, which can result in milestone payments and royalties based on sales performance. Additionally, the company may receive funding through grants or investments aimed at supporting its research and development initiatives.

Oculis Holding Financial Statement Overview

Summary

Oculis Holding faces substantial financial challenges, particularly in profitability and revenue growth, with negative margins across the board. While the company maintains a low debt-to-equity ratio, its equity has been declining. Cash flows are under pressure, with negative free cash flow and limited conversion of losses into operational cash flow. Strategic adjustments are necessary to improve financial health.

Income Statement

Oculis Holding's TTM (Trailing-Twelve-Months) income statement shows a gross profit margin of -5747.54% and a net profit margin of -18363.60%, indicating significant operational losses. The revenue growth rate is negative, showing a decrease of 47.11% from the previous year, and both EBIT and EBITDA margins are negative, further emphasizing ongoing financial struggles.

Balance Sheet

The balance sheet reveals a debt-to-equity ratio of 0.02, indicating low leverage, but stockholders' equity has decreased significantly over recent years. The equity ratio is 60.96%, showing a strong equity position relative to total assets, yet the company has faced equity erosion over time.

Cash Flow

Cash flow analysis shows a negative free cash flow growth rate of -11.43%. The operating cash flow to net income ratio is 0.55, reflecting operational inefficiencies. The free cash flow to net income ratio is 0.56, suggesting limited cash flow generation relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	245.00K	686.00K	883.00K	912.00K	960.00K	993.00K
Gross Profit	-16.22M	-51.40M	-28.36M	-21.31M	-8.61M	-8.34M
EBITDA	-102.88M	-72.80M	-45.73M	-31.95M	-12.98M	-12.10M
Net Income	-102.90M	-85.78M	-88.80M	-38.70M	-18.55M	-14.87M
Balance Sheet
Total Assets	204.17M	120.35M	114.35M	37.06M	58.04M	16.38M
Cash, Cash Equivalents and Short-Term Investments	181.93M	98.66M	91.65M	19.79M	46.28M	4.95M
Total Debt	1.10M	1.18M	605.00K	123.08M	114.27M	54.81M
Total Liabilities	41.55M	46.97M	20.63M	135.05M	119.00M	60.04M
Stockholders Equity	162.63M	73.38M	93.73M	-97.99M	-60.95M	-43.65M
Cash Flow
Free Cash Flow	-54.60M	-47.73M	-53.89M	-28.62M	-13.85M	-12.05M
Operating Cash Flow	-53.27M	-47.50M	-53.84M	-25.07M	-13.82M	-12.03M
Investing Cash Flow	-67.02M	-17.56M	-54.21M	-3.55M	-28.00K	-19.00K
Financing Cash Flow	157.68M	54.03M	129.67M	1.71M	55.19M	4.86M

Oculis Holding Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCS, the sentiment is Negative. The current price of 17.32 is below the 20-day moving average (MA) of 17.87, below the 50-day MA of 18.29, and below the 200-day MA of 18.50, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 37.63 is Neutral, neither overbought nor oversold. The STOCH value of 18.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OCS.

Oculis Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$818.57M	―	-43.63%	―	―	-13.05%
OCUL	56 Neutral	$2.14B	―	-63.41%	―	-7.26%	-15.33%
EYPT	55 Neutral	$829.89M	―	-73.95%	―	2.99%	-49.11%
MLYS	53 Neutral	$1.00B	―	-63.21%	―	―	-32.33%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
BCAX	48 Neutral	$656.94M	―	-32.71%	―	―	―
OCS	41 Neutral	$955.98M	―	-85.39%	―	―	-43.02%